This review synthesizes recent advances in pharmaco‐microbiomics, reframing cancer treatment in a hologenetic context, with host, tumor and microbiome acting as a tripartite entity, and establishes microbiome as a predictor and therapeutic target in precision medicine.
Abstract
This review synthesizes recent advances in pharmaco‐microbiomics, reframing cancer treatment in a hologenetic context, with host, tumor and microbiome acting as a tripartite entity. We comprehensively review microbiome‐mediated regulation of chemotherapeutic responses, encompassing both chemosensitization and resistance. At the molecular level, commensal microbiota enhance immunogenic cell death (ICD) and anti‐tumor immune responses, while intratumoral bacteria confer resistance through intracellular sequestration, induction of autophagy and drug inactivation (cytidine deaminase‐mediated gemcitabine degradation and β‐glucuronidase‐driven irinotecan toxicity). Our review also discusses systemic metabolic interactions including the “butyrate paradox”, competition for transporters, and microbiome‐mediated pharmacokinetics. Moving beyond microbiome profiling, we highlight functional metagenomics and resistome‐based patient stratification, complemented by AI‐based predictive modeling to predict non‐responders. In terms of translation, we outline next‐generation therapies such as engineered living medicines (ELMs), CRISPR‐bacteria for gene editing, precision bacteriophage therapy and postbiotic metabolites as precision approaches to reshape the tumor‐microbiome landscape. Finally, we present a clinical strategy combining microbiome companion diagnostics and co‐formulated “smart therapeutics” to combat multidrug resistance. This paradigm shift establishes microbiome as a predictor and therapeutic target in precision medicine.
Cancers develop within a host ecosystem in which kinds of factors such as gut and tumor‐resident microbiota influence the tumor microenvironment (TME) and therapeutic response. High‐throughput sequencing has revealed the presence of low‐biomass bacteria, fungi, and viruses across diverse malignancies, establishing the...
Juan Lu, Meng-Juan Xuan, Liang Yu et al.· MedComm· 0 citations
The Immuno-Oncology-Microbiome (IOM) axis is a tripartite regulatory system involving microbiota, immune cells, and tumors, which critically modulates cancer progression and therapy response. This systematic review synthesizes key advances from 2022 to 2025, illustrating the field’s evolution from macro-associations to...
Yi-Mao Wu, Fei-Yang Tang, G. Zengin et al.· The Innovation Oncology· 0 citations
Cytotoxic chemotherapy remains an important component of multimodal treatment for many solid tumors, but resistance and dose-limiting toxicities continue to constrain clinical benefit. The gut microbiome can influence chemotherapy response through microbial drug biotransformation, metabolite signaling, intestinal-barri...
Ting Shao, Ming-Hui Li, Shao-Lin Li et al.· Frontiers in Immunology· 0 citations
Cancer remains a major global health challenge, and growing evidence indicates that the gut microbiota plays an important role in cancer initiation, progression, metastasis, and response to treatment through complex interactions with host signaling, metabolism, and immunity. This comprehensive narrative review discusse...
P. Negi, Arpita Upreti, Preeti Budhlakoti et al.· Frontiers in Molecular Biosc...· 0 citations
Immune checkpoint inhibitors (ICIs) have transformed the treatment of multiple malignancies, yet durable clinical responses remain limited to a subset of patients. Accumulating evidence identifies the gut microbiome as a regulator of antitumour immunity that can influence treatment efficacy and toxicity through microbi...
M. Biazzo, M. Soriani, Marianna Micallef et al.· Microorganisms· 0 citations
Related blog posts
MIT News · Artificial Intelligence· news.mit.eduNov 13, 2026
What's new in research at Microsoft? Host Anson Ho explores the latest, including AI-powered universal translation, a breakthrough in a 31-year-old mathematics challenge, and advances making AI coding agents faster and more efficient. The post Microsoft Research Focus – Edition #98 appeared first on Microsoft Research.
MIT News · Artificial Intelligence· news.mit.eduNov 12, 2026
MIT scientists developed a training method to generate models that simulate the effects of human activities on climate much more quickly than other approaches.